GEN Exclusives

More »

GEN News Highlights

Back to Item »

GSK Pays Apeiron About $17.5M Up Front for Early Clinical-Stage ACE2 Candidate

Drug is in Phase I for acute respiratory distress syndrome, and Apeiron could earn almost $380 million in milestones.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?